Bio-Rad Laboratories Inc. - Ordinary Shares - Class B
BIO.B
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.41B
Close$
$147.57
59.6% downside
Current Fair Value
59.6% downsideOvervalued by 59.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.41 Billion |
|---|---|
| Enterprise Value | $11.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $27.87 |
| Beta | 1.11 |
| Outstanding Shares | 26,746,000 |
Return
| Return on Equity | 3.10% |
|---|---|
| Return on Assets | 2.17% |
| Return on Invested Capital | -6.18% |
Valuation & Multiples
| P/E Ratio | 43.96 |
|---|---|
| PEG | 260.62 |
| Price to Sales | 3.8 |
| Price to Book Ratio | 1.36 |
| Enterprise Value to Revenue | 4.31 |
| Enterprise Value to EBIT | -19.45 |
| Enterprise Value to Net Income | 50 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$1.78
Average shareholder expectationRevenue Estimate
$624.81 M
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$2.23
Average shareholder expectationRevenue Estimate
$649.94 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bio-Rad Laboratories Inc.
7,450 employees
CEO: Norman Schwartz Bio-Rad Laboratories, Inc. creates, manufactures, and markets products essential for life science research and clinical diagnostics. Its operations span globally, covering territories such as the United States, Europe, Asia, Canada, and ...